214: Pericardial Effusion (PEF) is a Major Independent Risk Factor Associated with a Significant Decrease in Survival in Pediatric Stem Cell Transplantation (SCT) Recipients  by Neier, M. et al.
80 Poster Session Ireversible encephalopathy syndrome within 50 days post transplan-
tation, all of them showed complete clinical and radiological resolu-
tion. Conclusion: Non-myeloablative HSCT using this
conditioning regimen for high risk pediatric patients with benign
hematological disorders appears to be promising and worth further
study.214
PERICARDIAL EFFUSION (PEF) IS A MAJOR INDEPENDENT RISK FACTOR
ASSOCIATED WITH A SIGNIFICANT DECREASE IN SURVIVAL IN PEDIAT-
RIC STEM CELL TRANSPLANTATION (SCT) RECIPIENTS
Neier, M., Bhatia, M., Baldinger, L., Silver, E., Morris, E., van de
Ven, C., Kleinman, C., Jin, Z.Z., Cairo, M.S. Columbia University,
New York, NY.
Background: SCT is the treatment of choice for a variety of pe-
diatric conditions. Potential post SCT morbidities include cardiac
toxicity. Rhodes et al (BMT 2005) reported that PEF was seen in
4.4% of pediatric SCT recipients. Risk factors for the development
of PEF have been thought to include GVHD, infection and/or un-
derlying disease. There is a paucity of information regarding the eti-
ology, prognosis, treatment and outcome of PEF in a large cohort of
pediatric SCT recipients.Objectives: To assess the incidence, risk
factors, outcome of PEF and the impact of PEF on overall survival
(OS) in pediatric SCT recipients.Method: Echocardiograms were
performed at baseline prior to 200 SCT (4 were ineligible for re-
view) in 156 patients and when patients had symptoms and/or signs
of cardiac or pericardial disease post SCT. Probability of and time
to PEFwere analyzed by Kaplan-Meier method and risk of PEF and
deathwere determined bymultivariate analysis. Covariates included
age, gender, ethnicity, conditioning regimen, risk status (CIBMTR
criteria), conditioning regimen, donor source, CMV status,
GVHD, and HLA match. Results: The mean age was 8.15 years
(1/- 6.25 years) with 88 males and 68 females. 102 patients received
allogeneic transplants, 34 of them received more than 1 transplant.
116 of 156 recipients had malignant disease. 100 of 156 patients had
ablative conditioning. The incidence of PEF was 14.7%. A multi-
variate analysis shows that older age, poor risk and unrelated cord
blood donor recipients are significantly associated with a risk of de-
veloping PEF with hazard ratios of 1.125 (1.051–1.205), 3.508
(1.502–8.191), and 5.080 (1.141–22.625), respectively. OS was sig-
nificantly decreased in patients with PEF versus without PEF (haz-
ard ratio 5 4.84, 95% CI, 2.814–8.322, p\0.0001). Furthermore,
in a multivariate analysis, there was a significant decrease in OS as-
sociated with PEF, CMV status and poor risk status with hazard ra-
tios of 3.296 (1.73–6.26), 1.89 (1.08–3.30) and 1.93 (1.12–3.3),
respectively. Conclusion: These results demonstrate an almost
15% incidence of PEF in pediatric SCT recipients. Older, poor
risk and UCB donor recipients may be at higher risk of developing
PEF. PEFwas associatedwith themost significant impact on overall
mortality independent of other risk factors. Improved prevention
and therapeutic strategies for development of PEF in post allo
SCT recipients may potentially reduce mortality in the future.215
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN WISKOTT
ALDRICH SYNDROME (WAS): A SINGLE CENTER EXPERIENCE IN 25 PA-
TIENTS
Bonfim, C.M.S., Koliski, A., Bitencourt, M.A., Quiroga, M.,
Setubal, D.C., Funke, V., Ruiz, J., Medeiros, L., Oliveira, M.,
Coutinho, E., Zanis Neto, J., de Medeiros, C.R., Pasquini, R. Federal
University of Parana, Curitiba, PR, Brazil.
WAS is a rare X-linked disease characterized by eczema, micro-
thrombocytopenia, recurrent infections, autoimmune complica-
tions and malignancies. The gene responsible for WAS has been
identified and termed WASP. Without a successful HSCT, the
prognosis of classical WAS with a complete absence of WASP ex-
pression is poor. In this report we analyze the outcome of 25 pts
transplanted in a single center in a developing country.Material and Methods: Period: 04/92–02/07; age:1–14 ys-
old(M:2 ys). Eight pts received bone marrow(BM) from HLA
matched (5 pts) or mismatched family donors(3 pts). 17 pts received
an unrelated cord blood(URD CB). Preparatory regimen: Busul-
fan(BU)16 mg/kg1Cyclophosphamide 120–200 mg/kg in 24 pts
or BU8 mg/kg 1 Fludarabine 125 mg/m2:1 pt. ATG(rabbit) was
added to patients transplanted from unrelated donors or mis-
matched family donors. GVHD prophylaxis: Cyclosporine(Csa)1
MTX:16 pts; Csa 1 steroids:8 pts and Csa 1 MMF:1 pt. After
2005, all pts submitted to an URD CB transplantation, received
Csa1MTX as GVHD prophylaxis if the TNC infused was . 3.0
 10*7/kg. Results: 21 pts(84%) are alive between 100 – 4745
days (M:790 d) after HSCT. All pts survived more than 28 days
and were evaluable for engraftment. Primary graft failure (PGF) oc-
curred in 2 pts (both URD CB 4/6) and one pt was submitted to
a successful 2nd transplant. Most pts tolerated the procedure very
well. See table below for transplant related complications.23/25
pts were analyzed for chimerism (VNTR). 13 pts had a complete
chimerism. Ten pts were mixed chimeras immediately after
HSCT and, later on, 3 pts became full chimeras. Four pts had auto-
immune complications after transplant: 3 pts had idiopathic throm-
bocytopenic purpura(ITP) and one pt had severe auto immune
hemolytic anemia (AIHA). Frequent viral infections (CMV, EBV,
adenovirus) occurred in pts submitted to URD CB transplants. 2/
21 surviving pts have permanent sequels from neurological viral in-
fections. Conclusions: The excellent survival in this group of pts
confirms the efficacy of HSCT in this disease. Pts receiving
HSCT from 4/6 URDCB have a lower survival. Reactivation of vi-
ral infections were frequent complications in our pts and should be
monitored closely.
Post-transplant complications
URD CB BM from BM fromCompatibility:
6/6 or 5/6
N 5 11 ptsURD CB
Compatibility:
4/6 N 5 6 ptsmatched family
donors
N 5 5 ptsmismatched
family donors
N 5 3 ptsGraft failure 0 2 0 0Acute GVHD
grade III-IV3/11 1/4 0 0Chronic GVHD
extensive2/11 1/4 0 0Mixed chimeras 3 pts 2 pts 2 pts 0Auto immune
complications0 2 pts (ITP
and AIHA)1 pt (ITP) 1 pt (ITP)Overall Survival 91% 66% 80% 100%Causes of death 1 pt: D 1
1825:
bronchopneumonia
1 respiratory
failure2 pts: D 1 34 :
PGF1 fungal
infection and
D 1 132 :
C-GVHD 1
bacterial sepsis1 pt:D 1 62:
CMV pneumonia
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IRON OVERLOAD IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) PATIENTS
Barry, E.V.1,2, Chirnomas, D.1,2, Barry, K.2, Duncan, C.N.1,2,
Lehmann, L.1,2. 1Dana-Farber Cancer Institute, Boston, MA; 2Chil-
dren’s Hospital Boston, Boston, MA.
Background: Iron can be a highly toxic molecule to cells and tis-
sues when it interacts with oxygen and generates free radicals. Free
iron, ferritin and transferrin saturation have been shown to increase
acutely in HSCT patients, and high ferritin levels can persist for
years following HSCT. The prevalence of iron overload has not
been defined in this population, and currently, no management
guidelines exist. We describe a group of pediatric HSCT patients
who were diagnosed with iron overload after developing liver func-
tion abnormalities and/or hyper-ferritinemia. Methods: We per-
formed a detailed retrospective review of patients identified as
having iron overload following allogeneic HSCT performed be-
tween 2001–2007. We included a subset of patients with known
